![Biomedicines | Free Full-Text | Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis Biomedicines | Free Full-Text | Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis](https://www.mdpi.com/biomedicines/biomedicines-10-01823/article_deploy/html/images/biomedicines-10-01823-g001.png)
Biomedicines | Free Full-Text | Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis
![Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study](https://www.natap.org/2021/images/110521/110321-5/1106216.gif)
Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study
![Full article: Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study Full article: Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study](https://www.tandfonline.com/cms/asset/566718b8-3b24-46b6-83c0-84be41740313/didr_a_331647_f0002_c.jpg)
Full article: Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study
![Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study](https://www.natap.org/2021/images/110521/110321-5/1106215.gif)
Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre
Adverse events after starting BIC/FTC/TAF. Abbreviations: BIC/FTC/TAF,... | Download Scientific Diagram
![Etude SOLAR: la stratégie de switch vers CAB/RPV LA se révèle non inférieure à une poursuite de la trithérapie BIC/FTC/TAF - VIH - jm update Spécialiste - lejournaldumedecin.com Etude SOLAR: la stratégie de switch vers CAB/RPV LA se révèle non inférieure à une poursuite de la trithérapie BIC/FTC/TAF - VIH - jm update Spécialiste - lejournaldumedecin.com](https://web.static-rmg.be/if/c_crop,w_2000,h_1133,x_0,y_0,g_center/c_fit,w_620,h_351/e2eaea9903475031c0285d3c51b62be1.jpg)
Etude SOLAR: la stratégie de switch vers CAB/RPV LA se révèle non inférieure à une poursuite de la trithérapie BIC/FTC/TAF - VIH - jm update Spécialiste - lejournaldumedecin.com
![Gilead's fixed-dose (BIC/FTC/TAF) combination for HIV show high tolerability - European Pharmaceutical Review Gilead's fixed-dose (BIC/FTC/TAF) combination for HIV show high tolerability - European Pharmaceutical Review](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/hiv-treatment.jpg)
Gilead's fixed-dose (BIC/FTC/TAF) combination for HIV show high tolerability - European Pharmaceutical Review
![Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study](https://www.natap.org/2021/images/110521/110321-5/1106211.gif)
Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study
![Switching from EFV/FTC/TDF to BIC/FTC/TAF maintains virologic suppression in people living with HIV | Latest news for Doctors, Nurses and Pharmacists | Pharmacy Switching from EFV/FTC/TDF to BIC/FTC/TAF maintains virologic suppression in people living with HIV | Latest news for Doctors, Nurses and Pharmacists | Pharmacy](https://pubmiddleware.mims.com/resource/image/4ADBAD65-D2F2-4BF0-B988-AC12013CCCF6/OriginalThumbnail/THUMBNAIL_shutterstock_533717242.jpg)
Switching from EFV/FTC/TDF to BIC/FTC/TAF maintains virologic suppression in people living with HIV | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
![Diagram comparing initial use BIC/TAF/FTC with switching to BIC/TAF/FTC... | Download Scientific Diagram Diagram comparing initial use BIC/TAF/FTC with switching to BIC/TAF/FTC... | Download Scientific Diagram](https://www.researchgate.net/publication/377497387/figure/fig1/AS:11431281224943894@1708497702280/Diagram-comparing-initial-use-BIC-TAF-FTC-with-switchingto-BIC-TAF-FTC-among-PLWH.jpg)
Diagram comparing initial use BIC/TAF/FTC with switching to BIC/TAF/FTC... | Download Scientific Diagram
![Randomized clinical trials of BIC/FTC/TAF and DTG/3TC in naïve patients. | Download Scientific Diagram Randomized clinical trials of BIC/FTC/TAF and DTG/3TC in naïve patients. | Download Scientific Diagram](https://www.researchgate.net/profile/Carlos-Rubio-Terres/publication/365596187/figure/tbl1/AS:11431281103295754@1669649228223/Preferred-starting-ART-combinations-recommended-by-GeSIDA-7_Q320.jpg)